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Abstract. The identification of biomarkers for Alzheimer’s disease is important for patient management and to assess the effec-
tiveness of clinical intervention. Cerebrospinal fluid (CSF) biomarkers constitute a powerful tool for diagnosis and monitoring
disease progression. We have analyzed the presence of fungal proteins and DNA in CSF from AD patients. Our findings reveal
that fungal proteins can be detected in CSF with different anti-fungal antibodies using a slot-blot assay. Additionally, amplifi-
cation of fungal DNA by PCR followed by sequencing distinguished several fungal species. The possibility that these fungal
macromolecules could represent AD biomarkers is discussed.
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The possibility that Alzheimer’s disease (AD) is
caused by a microbial infection has been considered by
a number of laboratories [1–4]. Several animal viruses
or bacteria have been suggested as the potential etiol-
ogy or as a risk factor for AD. For example, herpes
simplex virus type 1 (HSV-1) has been related to AD
[5–7], and viral genomes can be detected in amy-
loid plaques [8]. However, no significant differences
were found between normal elderly people and AD
patients for the presence of herpes DNA and signs of
viral replication [9]. Additionally, DNA from Chlami-
dophyla pneumoniae (formerly known as Chlamydia
pneumoniae) has been detected in a large percentage
of AD brains [10]; however, these findings could not
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be reproduced by other researchers [11, 12]. Antigens
and DNA from several infectious agents have been
found in cerebrospinal fluid (CSF) from AD suffer-
ers [1, 3, 4], including HSV-1 and C. pneumoniae
[13, 14]. More recently, we have proposed that dissem-
inated mycoses may play a part in the etiology of AD.
Accordingly, increased amounts of fungal polysaccha-
rides, proteins, and DNA were observed in peripheral
blood from AD patients [15] and proteomic and gene
sequencing analysis revealed proteins in AD brains and
also DNA from several species of fungi [16]. Moreover,
yeast cells can be directly visualized in AD brains,
both intra- and extracellularly, by immunohistochem-
istry using specific polyclonal antibodies raised against
fungi [17].
In the present work, we have evaluated whether fun-
gal proteins and DNA can be detected in CSF from AD
patients. As a first test, we used a slot-blot protocol as
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Table 1
Fungal antigens present in CSF samples from AD patients
Patients Age Gender C. famata C. albicans C. glabrata Enolase  tubulin peptide
Patient 1 91 Female 154 ± 6.2 143 ± 5.7 104 ± 5.2 173 ± 8.6 114 ± 5.7
Patient 2 80 Male ND 65 ± 3.2 ND 157 ± 4.5 30 ± 2.4
Patient 3 98 Female 77 ± 3.8 77 ± 3.8 53 ± 4.2 132 ± 4.3 225 ± 11.2
Patient 4 74 Female 9 ± 0.6 57 ± 3.4 37 ± 2.9 109 ± 3.9 47 ± 3.8
Patient 5 93 Female 1 ± 0.1 56 ± 3.5 44 ± 3.5 84 ± 3.6 78 ± 3.8
Patient 6 77 Female 26 ± 2.2 63 ± 3.2 22 ± 1.8 145 ± 5.8 82 ± 4.1
Patient 7 86 Male 16 ± 1.3 10 ± 1.2 29 ± 2.3 14 ± 1.2 1 ± 0.1
Patient 8 82 Male 42 ± 3.4 ND 26 ± 2.1 107 ± 5.3 7 ± 0.6
Patient 9 88 Female 74 ± 4.0 75 ± 4.1 37 ± 3.0 142 ± 7.1 34 ± 2.7
Patient 10 85 Male 122 ± 4.9 77 ± 3.7 130 ± 6.5 154 ± 7.7 63 ± 3.1
Mean value 57.8 69.2 53.5 121.7 68.1
Control 1 64 Male 26 ± 2.1 13 ± 0.9 15 ± 1.2 79 ± 3.9 10 ± 0.7
Control 2 43 Male 9 ± 0.7 20 ± 1.5 88 ± 2.8 79 ± 3.9 81 ± 3.2
Control 3 68 Female 1 ± 0.1 1 ± 0.1 5 ± 0.4 ND 1 ± 0.2
Mean value 12.0 11.3 36.0 79.0 30.6
P value 0.31 0.05 0.04 0.04 0.12
Odds ratio 4.0 16.0 18.0 18.0 8.0
The mean of the densitometric values of three experiments and the standard deviation are indicated. ND, not done.
previously described to measure fungal antigens [15].
Briefly, triplicate 40l samples of CSF were filtered
onto nitrocellulose membranes and incubated with
a range of polyclonal rabbit antibodies (1:500 dilu-
tion) raised against different species of fungi [18–20].
Following incubation with a horseradish peroxidase-
conjugated donkey anti-rabbit secondary antibody
(1:5000 dilution, Amersham Biosciences), the mem-
brane was exposed to X-ray film and densitometric
analysis was performed. Quantification obtained with
each anti-fungal antibody in CSF samples from AD
patients and controls is shown in Table 1. The majority
of CSF samples from AD patients gave high densito-
metric values with at least one of the antibodies, which
were above the cut-off values reported previously
[18, 19]. This was the case for AD patients 1–6, 9, and
10, whereas CSF from patients 7 and 8 produced rather
low values with the antibodies tested. The p value
and the odds ratio for each antibody employed are
shown in Table 1. Considering all the results gener-
ated, a global p value of 0.0016 and an odds ratio of 8
were obtained. Statistical analyses of the data obtained
were carried out using the Stata Program Version 11.0.
One possible explanation for the evident low values in
patients 7 and 8 is that they do not have a mycosis,
or perhaps the infection is present in the CNS but not
the CSF. Alternatively, the antigens present in these
patients may belong to a species of fungus that does
not crossreact with the antibodies employed in this
study. Yet another possibility is that the levels of fun-
gal antigens in CSF fluctuate during the course of the
disease. Elevated levels of these antigens in CSF have
been previously reported by our laboratory in patients
with multiple sclerosis or amyotrophic lateral sclero-
sis [18, 19], pointing to the concept that mycoses also
exists in these two neurodegenerative diseases. These
disseminated fungal infections may contribute as a risk
factor for these diseases or can play a part in their
etiology. Thus, in several neurodegenerative diseases
so far analyzed, CSF from some patients contains high
levels of fungal antigens.
A second sensitive test for mycosis detection is the
analysis of fungal DNA sequences after PCR amplifi-
cation. We have developed several nested PCR-based
Table 2
Fungal species present in CSF samples from AD patients detected by PCR
Species Patient 1 Patient 2 Patient 4 Patient 5 Patient 7 Patient 9
Candida albicans 2;3 2 1 1
Cladosporium 3
Cryptoccocus 1 1;2 1 2
Malasezzia globosa 1 1 1
Malasezzia restricta 1 1
Sacharomyces cerevisae 3
Numbers refer to the PCR amplification schedules that were positive for a given species. PCR 1: External ITS1 +
ITS-1 (internal 1). PCR 2: External ITS1 + ITS-1 (internal 2). PCR 3: External ITS1 + ITS-1 (internal 3).
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assays to amplify the internal transcribed spacer 1
(ITS-1) of the fungal genome [16, 18]. Amplified prod-
ucts can be separated on agarose gels and sequencing
of the corresponding PCR fragments establishes the
species present. The specific oligonucleotide primers
and conditions employed in these PCR assays have
been described in detail [18]. Special care should be
taken to avoid contamination during the PCR protocol
and the DNA extraction method. Using this procedure,
DNA was extracted from 200l of CSF using the
QIAmp (Qiagen) Genomic DNA Isolation Kit. Suf-
ficient material was only available from six patients
as indicated in Table 1. After DNA extraction, three
PCR assays were carried out. After a first-round PCR
of the ITS-1 region with external primers, three fur-
ther rounds of PCR were performed using different
internal primers (see scheme Supplementary Figure 1).
A typical PCR result is shown in Supplementary
Figure 1. As can been seen in this Figure, no DNA
products were amplified from controls for the PCR
assay and for the DNA extraction method. Also, no
DNA fragments appeared from DNA extracted from
control CSFs, suggesting that there is no skin contami-
nation. The products obtained with the three PCR were
separated on agarose gels and each individual band
was sequenced. All six CSF samples contained fun-
gal DNA and the species identified in each sample are
shown in Table 2. The species detected are potential
human pathogens and some of them have been previ-
ously found in brain samples from AD patients [16].
Curiously, only two out of six CSF samples contained
one fungal species, whereas in the other four patients
mixed fungal infections were revealed. Of interest, AD
patient 7, who was negative for fungal protein in the
slot-blot assay, was positive for fungal DNA. Collec-
tively, these data demonstrate that DNA from several
fungi can be detected in CSF from AD patients and,
more importantly, that the species can be identified
using this technique.
The search of potential biomarkers for neurodegen-
erative diseases in CSF has identified a number of
proteins that are altered in these patients [21–25]. This
is the case for amyloid- peptide, which is present in
reduced amounts in CSF from AD patients, whereas
tau protein is increased [26–28]. Interestingly, simi-
lar alterations in these proteins are also observed in
patients with CNS infections, including viral, bacterial,
protozoal and fungal infections [13, 29]; however, the
concentration of phosphorylated tau is usually normal
in some of these infections. These parallels between the
altered levels of amyloid and tau proteins in some neu-
rodegenerative diseases and microbial infections have
been ascribed to the induction of neuroinflammation.
Alterations in other proteins have also been proposed
as potential biomarkers for these diseases, for exam-
ple, the elevation in chitinase levels in [30–34] CSF
from AD, multiple sclerosis, and amyotrophic lateral
sclerosis patients. We have recently suggested that this
increase in chitinase may be related to the presence
of its substrate, i.e., fungal chitin [18]. In this regard,
our present findings provide additional support for the
possibility that components from different fungi are
present in AD patients. The anti-sera employed in this
work cross-react with a number of fungal proteins of
species different from the one used to obtain the anti-
serum. Therefore, the evidence of high levels of fungal
proteins in CSF using a given antiserum does not mean
that the fungal proteins present in CSF belong to the
antiserum species. Thus, the existence of fungal pro-
teins in CSF is indicative of a disseminated mycosis,
but does not provide unequivocally the fungal species
present. This can be achieved by DNA sequencing.
Thus, fungal macromolecules in CSF might constitute
new biomarkers for AD. Moreover, proteins from fungi
can be identified in peripheral blood serum, represent-
ing a much less invasive technique for patients [15].
The presence of fungal DNA is potentially more inter-
esting because it can indicate not only that a mycosis
exists, but also serves to identify the species responsi-
ble for the disseminated infection. In light our findings,
it will be interesting in future studies to analyze fun-
gal proteins and DNA in CSF from patients with early
cognitive decline, or even before the onset of AD symp-
toms are apparent. These analyses will indicate to what
extent the presence of fungal macromolecules in CSF
can be of prognostic value for AD.
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